Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up study of nivolumab across tumor types in prior nivolumab parent trials
MOH_2019-12-31_008530Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in Nonhematologic neoplasms and cancer (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Long-term safety. Started Dec 2019; status: recruiting.
02
Drugs
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on MOH_2019-12-31_008530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-12-31_008530.